Long-termers (such as myself) would know that there has been speculation at various times over the years, that NEU would be taken-over.
I'd argued against that and statements from the company subsequently ruled that out until the phase 3 results (at the earliest).
If trofinetide is approved, it would seem to me that it is almost certain that Acadia would make us an offer.
There has been chatter also that Baker Bros might be positioning Acadia for a sale. Approval of trofinetide would help if that was the case.
Maybe the SP action over the next 4 months might give us a hint as to either of those two possibilities playing out?
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 3 enrolment successfully completed, results in Q4 2021
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.04%
!
$13.24

Ann: Phase 3 enrolment successfully completed, results in Q4 2021, page-11
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.24 |
Change
0.390(3.04%) |
Mkt cap ! $1.652B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.253M | 324.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2 | $13.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.25 | 230 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 313 | 13.230 |
6 | 550 | 13.220 |
16 | 3126 | 13.210 |
8 | 1680 | 13.200 |
4 | 1270 | 13.190 |
Price($) | Vol. | No. |
---|---|---|
13.250 | 115 | 5 |
13.260 | 867 | 11 |
13.270 | 1648 | 10 |
13.280 | 1495 | 8 |
13.290 | 2261 | 6 |
Last trade - 12.16pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online